Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
.34's on deck, we're going up baby!!!!!!!!!!!!
Poniard Pharmaceuticals Announces Licensing Agreement
for Focal Adhesion Kinase Technology
SAN FRANCISCO, Calif. – November 18, 2011 – Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, announced today that it has entered into a licensing agreement with an undisclosed party for rights to Poniard’s focal adhesion kinase (FAK) technology, including a preclinical candidate that is a selective small molecule inhibitor of FAK.
Under terms of the agreement, Poniard granted the licensee worldwide rights for the development and commercialization of any FAK-related products, including the preclinical candidate, in exchange for an upfront cash payment of $250,000, milestone payments and other considerations, as well as royalty payments on net sales of any products covered by the license. The licensee is responsible for all costs related to further development and commercialization.
Also known as protein tyrosine kinase 2 (PTK2), FAK is associated with the invasion and metastasis of tumor cells. Inhibition of FAK activity is thought to decrease the mobility of certain cancer cells, reducing the potential for metastases. FAK is also thought to play a role in tumor formation and progression. Poniard’s FAK technology was developed through a research funding agreement with The Scripps Research Institute.
“Poniard’s FAK technology includes novel inhibitors against a pathway which plays a potentially critical role in the proliferation of cancer,” said Ronald A. Martell, chief executive officer of Poniard. “Our discovery and early research efforts in this area began in 2005 under a funded research agreement with the Scripps Research Institute. We look forward to the advancement of this technology and the opportunity to realize potential value through out-licensing and through our proposed merger with ALLOZYNE, which is subject to shareholder approvals.”
going over .30 soon!!
looking very good here near the end of day!
Where is everyone? PARD is heating up again! :)
I'd like to see a close betwenn .28-.30
This should gap up on Monday.
any time now :)
This is going up baby.
TANKING NOW....Friday PM > traders selling,
nice profits made here today.
PARD's float only 46 mill:
Float: 46.36M
% Held by Insiders1: 15.12%
% Held by Institutions1: 24.30%
Shorters will find out very soon that PARD is not going any lower, major covering soon.
Cutting edge technology developed here by PARD, only if one has lost a loved one to cancer will be able to fully understand the real inportance of not eliminating cancer cells for now but to stop it's growth wich equals to an opportunity to see the the cure some time in the future, GO PARD!!!!!!!!!
Almost ready for buy back time
That 100k on .3 is being destroyed right now me thinks.
I agree, .3 is where im in at. I wish i woulve waited a little more but im happy with my overall decision
Easy double at this price.
Resistance at .3 will become our new support.
We should blast through .29 and .30; which will become our base.
Record volume today, PARD looks very promissing.
100,000 bid support at 0.265
Congrats, I bought in at .3 and I dont think either of us will regret it.
100k Bid, now thats what im f*cking talkin about... this is bound to shoot up soon.
If we go above .3, there should be a nice support level created.. We shall see.
I think she's just about ready!!
I think there are alot of people very skeptical as to where this one is heading..
If we can get a triple or quadroople bounce, I believe we explode.
Chart setting up nicely for next run.
I sure hope we do! If not, no hard feelings I would like to close above .30
I think we might see .40 today :)
Followers
|
20
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
552
|
Created
|
05/31/07
|
Type
|
Free
|
Moderators |
http://www.poniard.com/
http://finance.yahoo.com/q/h?s=PARD
http://www.secform4.com/insider-trading/755806.htm
Poniard Pharmaceuticals, Inc., a biotechnology company, engages in the discovery, development, and commercialization of cancer therapy products in the United States. Its lead product is Picoplatin, a platinum-based cancer therapy, designed to overcome platinum resistance in the treatment of solid tumors. Picoplatin is in Phase II clinical trails in small cell lung cancer and is in Phase I/II trials for colorectal and hormone-refractory prostate cancers. The company has a collaboration agreement with The Scripps Research Institute on the discovery of novel, small-molecule, and multi-targeted protein kinase inhibitors and focal adhesion kinase inhibitors as therapeutic agents, including for the treatment of cancer. Poniard Pharmaceuticals was founded in 1984. It was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in 2006. The company is headquartered in South San Francisco, California.
[
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |